Display options
Cite
Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, et al. Immuno-PET Imaging to Assess Target Engagement: Experience from . J Nucl Med. 2019;60(7):902-909doi: 10.2967/jnumed.118.214726.
Menke-van der Houven van Oordt, C. W., McGeoch, A., Bergstrom, M., McSherry, I., Smith, D. A., Cleveland, M., Al-Azzam, W., Chen, L., Verheul, H., Hoekstra, O. S., Vugts, D. J., Freedman, I., Huisman, M., Matheny, C., van Dongen, G., & Zhang, S. (2019). Immuno-PET Imaging to Assess Target Engagement: Experience from . Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 60(7), 902-909. https://doi.org/10.2967/jnumed.118.214726
Menke-van der Houven van Oordt, C Willemien, et al. "Immuno-PET Imaging to Assess Target Engagement: Experience from ." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. 60,7 (2019): 902-909. doi: https://doi.org/10.2967/jnumed.118.214726
Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, McSherry I, Smith DA, Cleveland M, Al-Azzam W, Chen L, Verheul H, Hoekstra OS, Vugts DJ, Freedman I, Huisman M, Matheny C, van Dongen G, Zhang S. Immuno-PET Imaging to Assess Target Engagement: Experience from . J Nucl Med. 2019 Jul;60(7):902-909. doi: 10.2967/jnumed.118.214726. Epub 2019 Feb 07. PMID: 30733323; PMCID: PMC6604691.
Copy Download .nbib Format: NLM
Share it on

J Nucl Med. 2019 Jul;60(7):902-909. doi: 10.2967/jnumed.118.214726. Epub 2019 Feb 07.

Immuno-PET Imaging to Assess Target Engagement: Experience from .

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

C Willemien Menke-van der Houven van Oordt, Adam McGeoch, Mats Bergstrom, Iain McSherry, Deborah A Smith, Matthew Cleveland, Wasfi Al-Azzam, Liangfu Chen, Henk Verheul, Otto S Hoekstra, Danielle J Vugts, Immanuel Freedman, Marc Huisman, Chris Matheny, Guus van Dongen, Sean Zhang

Affiliations

  1. Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands [email protected].
  2. Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  3. OMID Molecular Imaging Consultancy, Uppsala, Sweden.
  4. Clinical Pharmacology, Science, and Study Operations, GlaxoSmithKline, Uxbridge, United Kingdom.
  5. Clin Pharm Advantage, LLC, Durham, North Carolina.
  6. Bioimaging, Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom.
  7. Biopharm Product Development and Supply, GlaxoSmithKline, King of Prussia, Pennsylvania.
  8. Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania.
  9. Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  10. Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  11. Freedman Patent, Harleysville, Pennsylvania.
  12. Oncology R&D, GlaxoSmithKline, King of Prussia, Pennsylvania; and.
  13. Hengrui Therapeutics, Inc., Princeton, New Jersey.

PMID: 30733323 PMCID: PMC6604691 DOI: 10.2967/jnumed.118.214726

Abstract

PET imaging with radiolabeled drugs provides information on tumor uptake and dose-dependent target interaction to support selection of an optimal dose for future efficacy testing. In this immuno-PET study of the anti-human epidermal growth factor receptor (HER3) mAb GSK2849330, we investigated the biodistribution and tumor uptake of

© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Keywords: HER3; antibody; dose selection; immuno-PET; target engagement

References

  1. Cell. 2000 Oct 13;103(2):211-25 - PubMed
  2. J Nucl Med. 2005 Jun;46(6):1023-7 - PubMed
  3. J Nucl Med. 2007 Jun;48(6):995-9 - PubMed
  4. Cell Mol Life Sci. 2008 May;65(10):1566-84 - PubMed
  5. Cancer Res. 2008 Jul 15;68(14):5878-87 - PubMed
  6. Clin Cancer Res. 2008 Dec 1;14(23):7843-9 - PubMed
  7. J Nucl Med. 2009 Nov;50(11):1828-36 - PubMed
  8. AAPS J. 2010 Mar;12(1):33-43 - PubMed
  9. Nat Protoc. 2010 Apr;5(4):739-43 - PubMed
  10. Cancer Biol Ther. 2010 Sep 15;10(6):555-63 - PubMed
  11. J Natl Cancer Inst. 2013 Feb 20;105(4):266-73 - PubMed
  12. MAbs. 2013 Mar-Apr;5(2):297-305 - PubMed
  13. Cancer Cell. 2013 May 13;23(5):603-17 - PubMed
  14. EJNMMI Res. 2013 Nov 23;3(1):77 - PubMed
  15. J Nucl Med. 2014 Feb;55(2):264-7 - PubMed
  16. Clin Cancer Res. 2014 Mar 15;20(6):1410-6 - PubMed
  17. Hum Vaccin Immunother. 2016 Mar 3;12(3):576-92 - PubMed
  18. Clin Cancer Res. 2016 Apr 1;22(7):1642-52 - PubMed
  19. Ann Oncol. 2016 Apr;27(4):619-24 - PubMed
  20. Front Pharmacol. 2016 May 24;7:131 - PubMed
  21. Oncotarget. 2016 Nov 29;7(48):80046-80058 - PubMed
  22. Cancers (Basel). 2017 Mar 24;9(4):null - PubMed
  23. PLoS One. 2017 Apr 27;12(4):e0176075 - PubMed
  24. J Nucl Med. 2017 Aug;58(8):1188-1195 - PubMed
  25. Clin Cancer Res. 2017 Oct 15;23(20):6128-6137 - PubMed
  26. J Cereb Blood Flow Metab. 1983 Mar;3(1):1-7 - PubMed

Substances

MeSH terms

Publication Types